ArticleScientific reports2025
Effect of 1,3,4-oxadiazoles on expression of biofilm-associated bap gene in clinical isolates of multidrug-resistant Acinetobacter baumannii.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of multidrug-resistant (MDR) pathogens, particularly Acinetobacter baumannii, poses a significant threat to global health due to its resistance to multiple antibiotics, biofilm-forming capacity, and associated poor clinical outcomes. This study aimed to evaluate the antibacterial and antibiofilm efficacy of 1,3,4-oxadiazole against A. baumannii, focusing on biofilm-related challenges and gene expression. A one-step, high-yield method was used to synthesize the 1,3,4-oxadiazoles. Thirteen A. baumannii isolates were collected from clinical samples and assessed for biofilm formation using microtiter plate assays. Antimicrobial susceptibility was determined via the Kirby-Bauer disk diffusion method, while the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of 1,3,4-oxadiazole were evaluated following CLSI guidelines. PCR was used to detect the presence of biofilm-associated (bap) gene. The inhibitory effect of 1,3,4-oxadiazole on biofilm formation and bap gene expression (using RT-qPCR) was assessed, alongside cytotoxicity testing on the A549 lung cancer cell line. Among eight selected clinical isolates, 100% were MDR, exhibiting high resistance to gentamicin, ciprofloxacin, and imipenem. Biofilm assays classified the isolates as strong, moderate, or weak producers, with the presence of the bap gene significantly associated with biofilm formation (p < 0.05). MIC and MBC values of 1,3,4-oxadiazole ranged from 7.81–31.25 µg/ml and 7.81–62.5 µg/ml, respectively. Sub-MIC concentrations significantly inhibited biofilm formation (43–79% reduction) and downregulated bap expression (log2-fold change: 0.24–4.13). Cytotoxicity analysis confirmed no significant effects on A549 cells at 15.62 and 7.81 µg (p = 0.085). 1,3,4-Oxadiazole exhibits significant antibacterial and antibiofilm properties against MDR A. baumannii, effectively targeting biofilm-associated genes and demonstrating a favorable safety profile. These findings highlight the potential of 1,3,4-oxadiazole as a promising candidate for combating MDR infections and biofilm-related complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.